Urinary Tract Health (UTI Support)

Urinary Tract Health and UTI Support: A Nutritional and Natural-Health Reference

1. Definition and Overview

A urinary tract infection (UTI) is a collective term for infections that involve any part of the urinary tract. The urinary tract includes the kidneys, the bladder, the urethra, and the ureter. UTI may be defined as a condition in which bacteria are established and multiplying within the urinary tract.

The UTI can be divided into two anatomical categories: lower UTI (urethritis, cystitis, and prostatitis) and higher UTI (acute pyelonephritis, renal abscess, and perinephric abscess). An uncomplicated UTI is a bacterial infection of the bladder and associated structures, occurring in patients without structural abnormalities of the urinary tract or comorbidities such as diabetes, an immunocompromised state, recent urologic surgery, or pregnancy. A simple UTI (or cystitis) is a urinary tract infection due to appropriate susceptible bacteria in a clinical context not associated with treatment failure or poor outcomes.

The incidence of UTIs in adult males aged under 50 years is low, with adult women being 30 times more likely than men to develop a UTI. Both males (12%) and females (40%) have at least one symptomatic UTI throughout their lives. In 2019, more than 400 million individuals had UTIs globally, and more than 200,000 people died of UTIs.

2. Presenting Symptoms and Clinical Manifestations

Typical UTI symptoms include urinary frequency, urgency, suprapubic discomfort, and dysuria. Infection of the bladder (e.g., cystitis) can result in pelvic pressure, lower abdomen discomfort, frequent and painful urination, and blood in the urine. Infection of the urethra (e.g., urethritis) typically includes a burning sensation associated with urination. Infection of the kidneys (e.g., acute pyelonephritis) can result in upper back and side pain, high fever, shaking and chills, nausea, and vomiting. These infections can also be asymptomatic.

3. Body Systems Involved

The infection of the urinary tract may result from microbial invasion of any of the tissues extending from the urethral orifice to the renal cortex. Although the infection and resultant symptoms may be localized, the presence of bacteria in urine places the entire urinary system at risk of invasion by bacteria.

The urogenital microbiome plays a critical role in UTI susceptibility. The vagina is a key anatomical site in the pathogenesis of UTI in women, serving as a potential reservoir for infecting bacteria and a site at which interventions may decrease the risk of UTI. Lactobacilli can prevent both the adherence, growth, and colonization of uropathogenic bacteria and have a strong inhibitory effect on uropathogenic E. coli (UPEC). Recent microbiological discoveries are providing an entirely new pathophysiological picture of recurrent UTIs; it is now clear that in the pathogenesis of UTIs, the microbiome plays a central role, and consequently, the exclusive use of antibiotics is not only ineffective but also counterproductive.

The most common pathogen causing UTIs, and in turn urosepsis, is Escherichia coli (50%), followed by Proteus (15%), Enterobacter (15%), Klebsiella (15%), Pseudomonas aeruginosa (5%), and gram-positive bacteria (15%). UPEC accounts for over 80% of community-acquired infections, whereas healthcare-related infections are predominantly caused by Staphylococcus, Klebsiella, Enterobacter, Proteus, and Enterococcus species.

4. Contributing and Associated Factors

4.1 Anatomical and Physiological Factors

Urinary tract infections predominantly affect women due to anatomical and physiological factors that facilitate bacterial colonization and invasion. The shorter urethra, proximity of the urethral opening to the anus, and hormonal changes during menstruation, pregnancy, and menopause increase the risk of UTIs in women. Pregnancy causes several physical, hormonal, and functional changes in the urinary tract, increasing urine stasis and the ascending of microbially contaminated urine from the bladder into the ureters. The changes in the urinary tract and immunological changes associated with pregnancy, along with an already short urethra, predispose women to UTIs.

4.2 Microbial and Microbiome-Related Factors

Studies have repeatedly shown that women with low levels of lactobacilli are more commonly colonized with vaginal E. coli than those with lactobacilli-dominated microbiomes, which naturally decrease the risk of UTI development. Recent studies confirm that many species of lactobacilli (most notably Lactobacillus crispatus) have the propensity to inhibit E. coli growth, likely through creating and maintaining a low pH environment. Furthermore, multiple studies in both non-pregnant and pregnant women show that bacterial vaginosis (characterized by the decrease of protective lactobacilli) increases the risk for colonization of the vaginal introitus and UTI development.

In a case-control study, women with recurrent UTI who lacked vaginal H₂O₂-producing lactobacilli had a 5-fold increased risk of E. coli vaginal colonization compared to women with H₂O₂-producing lactobacilli. Post-menopausal women can develop recurrent cystitis because the lowering of estrogens following menopause causes notable modifications of the vaginal microbiota, in particular a loss of lactobacilli.

4.3 Behavioral and Lifestyle Factors

Factors such as parity, history of abortion, sexual behavior, water intake, and urination habits have been identified as key contributors to the increased risk of UTIs. Among the risk factors that predispose women to contract recurrent cystitis are frequent sexual relations, having contracted their first UTI at less than 15 years of age, and a family history of UTIs. In a meta-analysis of children, poor fluid intake, infrequent voiding, and obesity significantly increased the occurrence of UTI, while breast-feeding and circumcision decreased it.

4.4 Comorbidities and Clinical Risk Factors

A systematic review and meta-analysis of hip fracture patients revealed 18 significant risk factors for UTI, including female sex (OR = 2.23), advanced age, obesity (OR = 1.21), catheterization (OR = 3.8), diabetes (OR = 1.27), dementia (OR = 1.82), and chronic steroid use (OR = 1.29). A systematic review of healthcare-associated UTI found the highest population-attributable risk associated with urinary catheterization, with the calculation that 79.3% of UTI would be prevented if catheterization was not performed.

Some antibiotic treatments (most commonly prescribed include ciprofloxacin, amoxicillin, ceftriaxone, fosfomycin, levofloxacin, and trimethoprim/sulfamethoxazole) can render the natural barrier of the urinary tract vulnerable to infections, producing a shift from Lactobacillus to coliform uropathogens.

5. Nutrients, Herbs, and Natural Ingredients

5.1 Cranberry (Vaccinium macrocarpon)

Traditional Use

Cranberry products have been used widely for several decades to prevent urinary tract infections. Cochrane reviews on this topic date back to one first published in 1998. Vaccinium macrocarpon Aiton (cranberry) is the best-studied home remedy for UTI. North American Indigenous communities and early European settlers used cranberry preparations for urinary complaints, a practice that evolved into widespread modern use of juices, tablets, and capsules.

Scientific Evidence

Cranberries contain proanthocyanidins (PACs), which inhibit the adherence of p-fimbriated Escherichia coli to the urothelial cells lining the bladder. Cranberry products have been used widely for several decades to prevent UTIs. PACs prevent the adherence of p-fimbriated Escherichia coli to the epithelium of the urinary bladder, thereby reducing the incidence of UTI.

The most comprehensive assessment to date is the 2023 Cochrane systematic review and meta-analysis. This update added a further 26 studies, taking the total number of studies to 50 with 8,857 participants. The data support the use of cranberry products to reduce the risk of symptomatic, culture-verified UTIs in women with recurrent UTIs, in children, and in people susceptible to UTIs following interventions. However, the evidence currently available does not support its use in the elderly, patients with bladder emptying problems, or pregnant women.

Forty-five RCTs compared cranberry with a placebo or no treatment. Taking cranberries as juice, tablets, or capsules reduced the number of UTIs in women with recurrent UTIs, in children with UTIs, and in people susceptible to UTIs following an intervention such as bladder radiotherapy. However, UTIs did not appear to be reduced in elderly institutionalized men and women, in adults with neuromuscular bladder dysfunction and incomplete bladder emptying, or in pregnant women.

A network meta-analysis published in 2024 found that a total of 20 trials (3,091 participants) were included, with 18 studies highlighting a 54% lower rate of UTIs with cranberry juice consumption than no treatment and a 27% lower rate than placebo liquid. Meta-analyses suggest a 24% reduction in UTI risk with a daily intake of ≥36 mg PACs, though variability in extract standardization and limited trial sizes highlight the need for further phase III studies.

Evidence strength: Moderate to strong for prevention of recurrent UTIs in women and children. Evidence is insufficient for treatment of active infections. Evidence is weak or absent in elderly institutionalized populations and pregnant women. Standardization of PAC content across products remains an ongoing limitation.

5.2 D-Mannose

Traditional Use

The interest toward D-mannose and UTIs dates back to the 1970s. D-mannose, a monosaccharide naturally found in fruits, is commonly marketed as a dietary supplement for reducing the risk of UTIs. Its use as a folk or traditional remedy predates formal study; it has been promoted as a natural alternative to antibiotics for decades in complementary medicine circles.

Scientific Evidence

When excreted in urine, D-mannose potentially inhibits Escherichia coli, the main causative organism of UTIs, from attaching to urothelium and causing infection. D-mannose may reduce UTI by preventing the adherence of bacteria to uroepithelium by binding to the type-1 pili and saturating the adhesin FimH.

An early randomized controlled trial found notable benefit. After initial antibiotic treatment of acute cystitis, 308 women with a history of recurrent UTI and no other significant comorbidities were randomly allocated to three groups. The first group (n = 103) received prophylaxis with 2 g of D-mannose powder in 200 ml of water daily for 6 months, the second (n = 103) received 50 mg nitrofurantoin daily, and the third (n = 102) received no prophylaxis. Overall, 98 patients (31.8%) had recurrent UTI: 15 (14.6%) in the D-mannose group, 21 (20.4%) in the nitrofurantoin group, and 62 (60.8%) in the no-prophylaxis group, with the rate significantly higher in the no-prophylaxis group. D-mannose powder had significantly reduced the risk of recurrent UTI, which was no different than in the nitrofurantoin group.

However, a large, rigorous 2024 double-blind RCT produced contrasting results. This 2-group, double-blind randomized placebo-controlled trial took place across 99 primary care centers in the UK. In this trial including 598 women with recurrent UTI, the proportion experiencing a medically attended UTI was 51.0% in those taking daily D-mannose over 6 months and 55.7% in those taking placebo. The authors concluded that D-mannose should not be recommended to prevent future episodes of medically attended UTI in women with recurrent UTI in primary care.

A 2025 meta-analysis of six RCTs corroborated the null finding. Six RCTs comprising 1,167 participants, of whom 534 received D-mannose and 521 (97.6%) were women, were included. D-mannose was not associated with a reduction in recurrent UTI compared with control (RR: 0.57, 95% CI 0.29–1.15) or antibiotics (RR: 0.39, 95% CI 0.12–1.25), and further analyses showed that D-mannose did not improve outcomes in a subgroup of postmenopausal women. In this meta-analysis of RCTs, D-mannose did not reduce the incidence of recurrent UTIs compared with control or antibiotics in high-risk patients.

D-mannose is well tolerated, with few reported adverse events; diarrhea was reported in about 8% of patients receiving 2 g of D-mannose for at least 6 months.

Evidence strength: Currently mixed and contested. Earlier smaller trials suggested benefit comparable to low-dose antibiotic prophylaxis; more recent and larger placebo-controlled trials do not confirm a statistically significant reduction in medically attended recurrent UTIs. Overall, recent systematic reviews do not support D-mannose as a reliable prophylactic agent. Further high-quality research is warranted.

5.3 Uva Ursi / Bearberry (Arctostaphylos uva-ursi)

Traditional Use

Uva ursi — otherwise known as Arctostaphylos uva-ursi or bearberry leaf — is an herbal remedy for UTIs that has been used in traditional and folk medicine practices for centuries. It is derived from a type of wild, flowering shrub that grows across various parts of Europe, Asia, and North America. The plant's berries are a favorite snack for bears — hence the nickname "bearberry leaf" — while its leaves are used to make herbal medicine. Traditional North American practice, as well as European herbal medicine dating back centuries, focused on the leaf for urinary tract support. Traditional preparations included dried leaf tea and liquid extracts, used primarily for short-term management of cystitis symptoms.

Scientific Evidence

Arctostaphylos uva-ursi (uva ursi), also known as bearberry or upland cranberry, is a useful herb for bladder infection. Bearberry leaves and preparations made from them have significant antibacterial activity (especially against E. coli) and astringent activity due to their arbutin content and diuretic properties. The primary active compound in uva ursi is arbutin, which is metabolized in the body into hydroquinone. This conversion occurs in the urinary tract, where hydroquinone exerts a direct antiseptic effect.

In a double-blind study of 57 women, five of twenty-seven women had a recurrence in the placebo group while none of thirty women had a recurrence in the uva ursi group after 1 year. However, this is a single small study. Lab studies show uva ursi kills UTI-causing bacteria, but the largest clinical trial (382 women) found no benefit for treating active UTI symptoms. One small study suggests it may help prevent recurrent UTIs when combined with dandelion, though more research is needed.

Modern research supporting the use of uva ursi to treat UTIs is limited, though several compounds present in the plant have exhibited potent antimicrobial capabilities in test-tube studies. No studies on A. uva-ursi supplementation in relation to urinary infections could be found in a 2025 narrative review.

It is important to consider the safety of bearberry consumption. Prolonged ingestion of bearberry can lead to intoxication and liver or kidney problems, but the maximum safe quantities are not well referenced. Uva ursi is absolutely contraindicated in pregnancy and during lactation — this is a firm contraindication in the EMA HMPC monograph, not merely a cautionary note.

Evidence strength: Preliminary and largely preclinical. In vitro antibacterial data are promising. One small RCT suggests possible benefit for recurrence prevention, but the largest clinical trial showed no benefit for acute UTI treatment. Clinical evidence is insufficient to support routine use, and safety concerns limit long-term application.

5.4 Probiotics (Lactobacillus Species)

Traditional Use

The use of fermented foods and cultures containing live bacteria to support health has ancient roots in many civilizations globally. Probiotics are helpful in establishing and maintaining normal ecology of the vagina, urethra, and bladder and a proper bladder pH, and are useful in preventing recurrent UTI. Lactobacilli are present predominantly in the urogenital flora of healthy reproductive-aged women, but the flora is disturbed following long-term antibiotic administration and post menstruation temporarily, and in post-menopausal women permanently.

Scientific Evidence

Due to their inherent ability to migrate along the gastrointestinal tract to the rectum and anus, lactobacilli bacteria can move to the urethra and vagina. This migration potential suggests that lactic acid-producing bacteria might positively influence the urogenital microflora by effectively adhering to the epithelial urogenital tracts and displacing uropathogenic microorganisms. Adhesion can be impeded through exclusion, where lactobacilli occupy binding sites, preventing the initial binding of uropathogens, and through competition, where lactobacilli vie with uropathogens for available adhesion receptors on epithelial cells.

In a case-control study, women with recurrent UTI who lacked vaginal H₂O₂-producing lactobacilli had a 5-fold increased risk of E. coli vaginal colonization. In another study of reproductive-age women, 15% of 301 women who had vaginal colonization with L. crispatus or L. jensenii, both H₂O₂-producers, were colonized with E. coli, compared with 27% of women who did not have these lactobacilli species present (P = 0.01).

Antibiotics may eradicate the bacterial infection, but they create intestinal dysbiosis, triggering a vicious circle. Interventions that target the gut microbiota or its metabolites may offer novel therapeutic avenues for reducing bacterial translocation and improving bladder health.

When UTIs occur with a frequency of at least three times per year or two times in the last six months, this is defined as recurrent UTI (rUTI), and up to 70% of women will have rUTI within 1 year. It was previously thought that antibiotic resistance was principally responsible for the recurrence of UTIs, but new diagnostic technologies have shown the role of microbiota in the pathophysiology. A personalized, multi-modal approach, treating vaginal and urinary dysbiosis, may reduce rUTIs more successfully.

Laboratory and clinical studies suggest that these natural interventions may reduce the incidence of UTIs by inhibiting pathogen adhesion, modulating immune responses, and promoting urinary tract health.

Evidence strength: Mechanistic and observational evidence is strong for the protective role of vaginal lactobacilli. Clinical trial evidence for probiotic supplementation specifically as UTI prophylaxis is promising but remains heterogeneous and inconclusive due to variability in strains, doses, and formulations studied.

5.5 Vitamin C (Ascorbic Acid)

Traditional Use

Supplemental vitamin C has been advocated in naturopathic and folk medicine traditions for urinary health, based on the longstanding belief that ascorbic acid acidifies urine, creating an inhospitable environment for bacteria.

Scientific Evidence

Vitamin C exhibits antioxidant and antimicrobial properties, acidifying urine to inhibit bacterial growth and potentially enhancing the efficacy of antibiotics. Supplement of vitamins A and C has been considered to be effective to prevent UTI. However, the clinical evidence base is limited. After decades of research, only two randomised trials have tested vitamin C for urinary tract infections, and they reached opposite conclusions. Vitamins C, E, and A have shown promising results as adjuvant therapies in UTI in pediatric populations, and a UTI is a type of infection that can occur in any part of the urinary system, including the kidneys, bladder, and urethra.

Evidence strength: Preliminary and mixed. In vitro and animal data show some antimicrobial activity, and a small number of clinical trials have been conducted; results are inconsistent. Current evidence does not establish vitamin C as a reliable standalone preventive strategy for UTIs in the general population.

5.6 Berberine and Goldenseal (Hydrastis canadensis)

Traditional Use

The dried rhizome and root of goldenseal contain the alkaloid berberine, which has antibacterial, antifungal, and some antimycobacterial and antiprotozoal activity. Berberine from goldenseal is thought to potentially prevent pathogenic bacteria, such as E. coli, from binding to the bladder wall. Traditional dose is as a tea taken three times daily. Goldenseal has been used in North American traditional herbal medicine for urinary complaints and as a general anti-infective remedy.

Scientific Evidence

Barberry (rich in berberine) and related plants exhibit broad-spectrum antimicrobial properties, including antibacterial, antifungal, and antiviral activity, which may be particularly beneficial against non-bacterial uropathogens. Berberine and uva ursi are cited in natural therapeutics literature as being prescribed for acute UTI.

Berberine, by contrast, has zero standalone clinical trials for UTI treatment or prevention. Berberine has no comparable clinical trial data for UTI prevention when used alone. Its berberine content also has very low oral bioavailability, meaning little reaches the urinary tract after oral ingestion.

Evidence strength: Preclinical only. No human clinical trials have evaluated berberine or goldenseal as standalone agents for UTI prevention or treatment. The bioavailability limitations further complicate extrapolation from in vitro data.

5.7 Garlic (Allium sativum)

Traditional Use

Garlic has been used in traditional medicine systems across diverse cultures for thousands of years, including for infections of the genitourinary tract. Its antimicrobial properties have long been attributed to its organosulfur compounds, primarily allicin.

Scientific Evidence

Garlic (which contains allicin) exerts antimicrobial effects by targeting thiol-containing enzymes, DNA gyrase, and oxidative stress pathways. The need for alternative or adjunctive therapies has spurred interest in plant-based treatments, which offer antimicrobial, anti-inflammatory, antioxidant, and immune-modulatory benefits. Notable candidates include cranberry, bearberry, pomegranate, green tea, and other phytochemicals with proven anti-adhesive and biofilm-disrupting properties.

Evidence strength: Largely preclinical and in vitro. While garlic compounds demonstrate bactericidal properties against uropathogens in laboratory studies, no well-designed human clinical trials specifically evaluating garlic for UTI prevention or treatment have been identified in the peer-reviewed literature.

5.8 Other Plant-Based Ingredients Discussed in the Literature

Flavonoids, a major class of polyphenols, show broad-spectrum anti-infective activity through membrane disruption, inhibition of nucleic acid synthesis, and enzyme interference. Roots rich in organosulfur and polyphenolic compounds, such as ginger (a source of gingerols) and turmeric (which provides curcumin), also exert antimicrobial effects; notably, curcumin nanoparticles have been reported to enhance the efficacy of fluoroquinolones against MDR bacterial isolates. Echinacea contributes primarily through immunomodulatory effects, potentially supporting host defense in urinary tract infections. Evidence for all these agents in a UTI-specific context is preliminary, largely preclinical, or limited to in vitro studies.

6. Dietary and Lifestyle Factors

6.1 Fluid Intake and Hydration

Hydration is among the best-supported lifestyle strategies in the UTI literature. An important modifiable determinant of UTI recurrence is water intake, as increased hydration may be beneficial in the dilution and flushing of bacteriuria. The frequent voiding that results from high fluid intake is thought to prevent the proliferation of bacteria.

The foundational RCT in this area enrolled 140 premenopausal women. One hundred and forty women suffering from recurrent UTI with low fluid intake and low urine volume were randomly assigned to increase their daily water intake by 1.5 L or to maintain their usual intake for 12 months. Increasing water intake (to 2.8 L/day) and urine volume (to 2.2 L/day) resulted in a 48% reduction in UTI events. Of note, a second benefit to increasing water intake was a reduction of antibiotic use, for prophylaxis or treatment of UTI.

Increased water intake is an effective antimicrobial-sparing strategy to prevent recurrent cystitis in premenopausal women at high risk for recurrence who drink low volumes of fluid daily. A subsequent systematic review and meta-analysis confirmed these trends. The seven meta-analysed RCTs suggest that increased fluid intake leads to a statistically significant reduction in the number of people with recurrent UTIs at ≤6 months, and there was also a significant decrease in the total number of UTIs. Given the minimal potential for harm of increased fluid intake, this review suggests considering clinically adopting its results and advising patients with recurrent UTIs to drink more to reduce recurrent UTIs.

6.2 Voiding Habits

In the pediatric population, poor fluid intake and infrequent voiding significantly increased the occurrence of UTI in a systematic review and meta-analysis. Regular, complete bladder emptying is widely discussed in the urological literature as a protective behavior, as urinary stasis allows bacteria to multiply without mechanical flushing.

6.3 Diet Composition and Weight

Obesity significantly increased the occurrence of UTI in children in a systematic review and meta-analysis. Obesity was identified as a significant risk factor for UTI in geriatric hip fracture patients (OR = 1.21) in a systematic review and meta-analysis published in 2024. Diets that support a healthy weight and provide dietary fiber to support intestinal microbiome diversity are discussed in the context of urogenital health, as the gut–urogenital microbiome axis is increasingly recognized.

6.4 Microbiome Modulation Through Diet

In the pathogenesis of UTIs, the microbiome plays a central role, and the exclusive use of antibiotics is not only ineffective but also counterproductive; antibiotics may eradicate bacterial infections but create intestinal dysbiosis, triggering a vicious circle. Interventions that target the gut microbiota or its metabolites may offer novel therapeutic avenues for reducing bacterial translocation and improving bladder health. Fermented foods providing live Lactobacillus species — including yogurt, kefir, and certain probiotic-fortified foods — are discussed in the naturopathic literature as dietary approaches to restoring protective vaginal and urogenital flora.

6.5 Hygiene and Behavioral Practices

Younger women, particularly those pregnant, were found to be at a higher risk, likely due to physiological changes during pregnancy and increased sexual activity. Sexual activity is a recognized independent risk factor for UTI in women, and post-coital voiding is commonly discussed in behavioral UTI-prevention guidelines, though rigorous controlled trials specifically on this behavior remain limited. Avoidance of spermicide-containing contraceptives is also discussed in the urological literature, as these products can disrupt vaginal lactobacilli.

References

• Tan CW, Chlebicki MP. Urinary tract infections in adults. Singapore Med J. 2016; PMC5027397
• Belyayeva M, Jeong JM. Uncomplicated Urinary Tract Infections. StatPearls. NIH/NCBI. 2025.
• Sabih A, Leslie SW. Complicated Urinary Tract Infections. StatPearls. NIH/NCBI. 2024.
• Ramanathan R, et al. Urosepsis. StatPearls. NIH/NCBI. 2023.
• Nicolle LE. Approach to urinary tract infections. Geriatr Aging. 2010; PMC2875701.
• Shaikh N, et al. Meta-analysis of the Risk Factors for Urinary Tract Infection in Children. Front Pediatr. 2022; PMC9508987.
• Wang W, et al. Risk factors for urinary tract infection in geriatric hip fracture patients: a systematic review and meta-analysis. Front Med. 2024; PMC10884186.
• Correlates of Urinary Tract Infections Among Women of Reproductive Age in India: A Systematic Review. PMC11107389.
• Williams G, Hahn D, Stephens JH, Craig JC, Hodson EM. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev. 2023; CD001321.
• Jepson RG, et al. Cranberries for treating urinary tract infections. Cochrane Database Syst Rev. 2023; CD001322.
• Cranberry Juice, Cranberry Tablets, or Liquid Therapies for Urinary Tract Infection: A Systematic Review and Network Meta-analysis. 2024.
• Preventive effect of cranberries with high dose of proanthocyanidins on urinary tract infections: a meta-analysis and systematic review. Front Nutr. 2024.
• Lenger SM, et al. Role of D-mannose in urinary tract infections — a narrative review. Nutr J. 2022.
• Kranjčec B, Papeš D, Altarac S. D-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial. World J Urol. 2014;32(1):79–84.
• d-Mannose for Prevention of Recurrent Urinary Tract Infection Among Women: A Randomized Clinical Trial. PMC11002776.
• D-mannose for Prevention of Recurrent Urinary Tract Infection in Adult Women: An Updated Systematic Review and Meta-analysis. PMC11776761.
• Efficacy of D-mannose as prophylaxis of recurrent urinary tract infection: a systematic review and meta-analysis of randomized controlled trials. PMC12471090.
• Cicero AFG, et al. Role of D-Mannose in the Prevention of Recurrent Uncomplicated Cystitis: State of the Art and Future Perspectives. Nutrients. 2021.
• Natural therapeutics for urinary tract infections — a review. Future J Pharm Sci. 2020; PMC7498302.
• Plant Extracts and Natural Compounds for the Treatment of Urinary Tract Infections in Women: Mechanisms, Efficacy, and Therapeutic Potential. PMC12384774.
• Probiotics and Plant-Based Foods as Preventive Agents of Urinary Tract Infection: A Narrative Review of Possible Mechanisms Related to Health. Nutrients. 2025.
• Stapleton AE. The Vaginal Microbiota and Urinary Tract Infection. Microbiol Spectr. 2016; PMC5746606.
• Gut Microbiome Implication and Modulation in the Management of Recurrent Urinary Tract Infection. PMC11677343.
• Microbiota Ecosystem in Recurrent Cystitis and the Immunological Microenvironment of Urothelium. PMC9956625.
• The Role of Gut, Vaginal, and Urinary Microbiome in Urinary Tract Infections: From Bench to Bedside. Diagnostics. 2021.
• Scott AM, et al. Increased fluid intake to prevent urinary tract infections: systematic review and meta-analysis. Br J Gen Pract. 2020; PMC6988703.
• Hooton TM, et al. Effect of Increased Daily Water Intake in Premenopausal Women With Recurrent Urinary Tract Infections: A Randomized Clinical Trial. JAMA Intern Med. 2018.
• Water intake and recurrent urinary tract infections prevention: economic impact analysis in seven countries. PMC10623695.
• Naturopathic Management of Urinary Tract Infections: A Retrospective Chart Review. PMC8713254.
• The Role of Vitamins in Pediatric Urinary Tract Infection: Mechanisms and Integrative Strategies. PMC12025032.
• U.S. Department of Veterans Affairs. Urinary Tract Infections. Whole Health Library.